IL2 and neoplasm: To test whether nanobodies specific to the EIIIB domain of FN can be used for targeted delivery and persistence of cytokines in the tumor ECM, we expressed murine IL-2 fused to the NJB2 nanobody, previously shown to bind EIIIB with 2 nM affinity (9).